Press release
Anemia And Other Blood Disorder Drugs Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033
Anemia And Other Blood Disorder Drugs Market
The Business Research Company's Anemia And Other Blood Disorder Drugs Global Market Report 2024 identifies the increasing prevalence of anemia among the global populationas the major driver for the anemia and other blood disorder drugs market's growth in the forecast period.Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the anemia and other blood disorder drugs market.
The anemia and other blood disorder drugs market size has grown strongly in recent years. It will grow from $11.13 billion in 2023 to $11.91 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, aging population, pharmaceutical innovation, patient awareness.
The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $15.49 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging markets, global demographics, economic factors. Major trends in the forecast period include research and development, technological advances, biologics and targeted therapies, gene therapies, telemedicine and remote monitoring, orphan drug designations, mergers and acquisitions.
Download Free Sample Of Anemia And Other Blood Disorder Drugs Market Report - https://www.thebusinessresearchcompany.com/sample_request?id=2465&type=smp
Major competitors in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc.
A key trend in the anemia and other blood disorder drugs market includes technological advancement. Major companies operating in the anemia and other blood disorder drugs market are increasing their focus on introducing novel medications to gain a competitive edge in the market. Novel medications refer to pharmaceutical products that represent a significant advancement or a new approach to the treatment of medical conditions or diseases. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis-stimulating agent (ESA) in MDS-related anemia based on interim results from pivotal Phase 3 COMMANDS. The approval was supported by data from the COMMANDS study, a global phase 3 trial in which nearly twice as many patients treated with Reblozyl achieved transfusion independence of at least 12 weeks and a concurrent hemoglobin increase compared to Epoetin alfa.
Read More On The Global Anemia And Other Blood Disorder Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report
The anemia and other blood disorder drugs market is segmented -
• By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
• By Route of Administration: Oral, Injectable
• By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the anemia and other blood disorder drugs market.
The Business Research Company's "Global Anemia And Other Blood Disorder Drugs Market Report 2024" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.
Explore Buying Options For The Anemia And Other Blood Disorder Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2465
The Table Of Content For The Anemia And Other Blood Disorder Drugs Market Include:
1. Executive Summary
2. Anemia And Other Blood Disorder Drugs Market Characteristics
3. Anemia And Other Blood Disorder Drugs Market Trends And Strategies
4. Anemia And Other Blood Disorder Drugs Market - Macro Economic Scenario
5. Global Anemia And Other Blood Disorder Drugs Market Size and Growth
……
31. Global Anemia And Other Blood Disorder Drugs Market Competitive Benchmarking
32. Global Anemia And Other Blood Disorder Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market
34. Anemia And Other Blood Disorder Drugs Market Future Outlook and Potential Analysis
35. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anemia And Other Blood Disorder Drugs Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033 here
News-ID: 3337453 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Anemia
Chemotherapy-Induced Anemia Market Forecast by Type Mild Moderate Severe and Lif …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Chemotherapy-Induced Anemia Market- (By Type of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia), By Treatment Type (RBC Transfusion, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, and Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)), By Region, Trends, Industry Competition…
Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Mark …
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Chemotherapy-Induced Anemia Market Size During the Forecast Period?
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This…
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM.
DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Anemia Drugs Market 2018 Grow at CAGR of 8.4% to Reach USD 34.7 Billion | By Uni …
Market Research Future Published a Prime research Report on “Global Anemia Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022
Global Anemia Drugs Market - Segments
Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration;…
Anemia in Chronic Kidney Disease (Renal Anemia) - Industry Analysis, Trends, and …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Anemia in Chronic Kidney Disease Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196648
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017,…
